BioSpace News Archive

POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare disorders, announced the completion of enrollment in DESTINY-1 Efficacy and Safety Trial In NASH), a dose-ranging Phase 2 trial evaluating PXL065 for the treatment of NASH.

External counterpulsation is a non-invasive and medically proven treatment recommended for patients with angina or congestive heart failure condition.

TMR Research has rich experience in developing state-of-the-art reports for a wide array of markets and sectors.

Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

Radialogica LLC and ScientificRT GmbH announced they are collaborating with IRCCS Sacro Cuore-Don Calabria Cancer Care Center in Negrar, Verona, Italy, to define requirements and validate support for Elekta’s Unity treatment machine in Radialogica’s SciMoCa® plan QA software.

Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced the opening of its new corporate headquarters and laboratory facility located in the heart of South Lake Union – Seattle’s life sciences hub.

Abeona Therapeutics Inc., a fully-integrated leader in gene and cell therapy, announced Board appointments, executive leadership promotions, and additions of senior regulatory veterans to prepare for the potential of two Biologics License Application submissions for EB-101 and ABO-102 currently in pivotal studies.

InnovAge Holding Corp. (the “Company” or “InnovAge”) (Nasdaq: INNV), a market leading healthcare delivery platform for high-cost, dual-eligible seniors, announced financial results for its fiscal fourth quarter and full year ended June 30, 2021.

Leap Therapeutics, Inc. today announced that it has commenced an underwritten public offering of its common stock

Heron Therapeutics, Inc. today announced that Barry Quart, Pharm.D., Chairman and Chief Executive Officer, and John Poyhonen President and Chief Commercial Officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 1:20 pm ET.